Tg Therapeutics (TGTX) Net Cash Flow (2011 - 2026)

Tg Therapeutics' Net Cash Flow history runs 16 years deep, the most recent figure standing at $363.1 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 860.34% year-over-year to $363.1 million in Q1 2026; TTM through Mar 2026 was $310.1 million, a 447.19% increase from a year earlier, with the FY2025 full-year figure at -$100.7 million, down 215.78% from the prior year.
• Net Cash Flow grew to $363.1 million in Q1 2026 per TGTX's latest filing, from $5.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $363.1 million in Q1 2026 and bottomed at -$113.2 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$15.9 million (2024), against an average of $8.4 million.
• Across the five-year window, Net Cash Flow tumbled 667.56% in 2023 and soared 860.34% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$7.6 million in 2022, then tumbled by 667.56% to -$58.0 million in 2023, then soared by 72.53% to -$15.9 million in 2024, then surged by 131.9% to $5.1 million in 2025, then soared by 7047.07% to $363.1 million in 2026.
• Per Business Quant, the three latest TGTX Net Cash Flow figures stand at $363.1 million (Q1 2026), $5.1 million (Q4 2025), and -$55.0 million (Q3 2025).